Drugs that contain Niacin
1. Niaspan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Feb, 2014
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
| US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) | |
Market Authorisation Date: 28 July, 1997
Treatment: An intermediate release nicotinic acid formulation suitable for oral administration once-a-day as a single dose for treating hyperlipidemia without causing drug-induced hepatotoxicity or elevations in...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NIASPAN family patents
2. Niaspan Titration Starter Pack patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
Market Authorisation Date: 28 July, 1997
Treatment: An intermediate release nicotinic acid formulation suitable for oral administration once-a-day as a single dose for treating hyperlipidemia without causing drug-induced hepatotoxicity or elevations in...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NIASPAN TITRATION STARTER PACK family patents